Aclaris therapeutics announces top-line results from 12-week phase 2b trial of oral zunsemetinib (ati-450) for moderate to severe rheumatoid arthritis and provides corporate update

— study did not meet primary or secondary efficacy endpoints in rheumatoid arthritis — — efficacy results do not support further development of zunsemetinib — — company to host conference call and webcast today at 8:00 am et — wayne, pa., nov. 13, 2023 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced top-line results from a phase 2b study of zunsemetinib (ati-450), an investigational oral mk2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (ra; ati-450-ra-202).
ACRS Ratings Summary
ACRS Quant Ranking